Patent · US Active

Autoantibody biomarkers of ovarian cancer

US12287337B2 · kind B2 · utility

0Cited by

0References

20Claims

0Family size

Assignee

ADELAIDE RESEARCH & INNOVATION PTY LTD · AU

Inventors

Peter Hoffmann · Senden, DE
Martin Oehler · Leingarten, DE
Karina Martin · Salisbury, AU

Key dates

Filing date	May 27, 2022
Grant date	Apr 29, 2025
Priority date	—
Expiry date	Jun 10, 2043

Classification

Technology area (CPC G)Physics
CPC primaryG01N2500/00
WIPO fieldMeasurement
WIPO sectorInstruments

Abstract

The present invention relates to the identification of biological markers of ovarian cancer. Specifically, cancer-associated autoantibodies to ANXA1, ARP3, SAHH, SERPH, ARAP1, OTUB1, ATP1A1, UBA1, and CFAH have been identified in subjects with early stage ovarian cancer. These autoantibodies can be utilised for a range of purposes including methods for detecting ovarian cancer, methods for screening for early stage ovarian cancer, and methods for assessing treatment response as well as disease progression and recurrence. The autoantibodies also represent prognostic markers of ovarian cancer development.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.